The loading rate determines tumor targeting properties of methotrexate albumin conjugates in rats

@article{Stehle1997TheLR,
  title={The loading rate determines tumor targeting properties of methotrexate albumin conjugates in rats},
  author={Gerd Stehle and Hannsjörg Sinn and Andreas Wunder and Hans Hermann Schrenk and Svenja Sch{\"u}tt and W Maier-borst and Dieter L. Heene},
  journal={Anti-Cancer Drugs},
  year={1997},
  volume={8},
  pages={667-685}
}
Albumin dominates the plasma proteins in man. Following our observation that albumin turnover in rodent tumors is markedly increased, we will present evidence that albumin can be employed as an efficient carrier for targeting cytostatic agents like methotrexate (MTX) into tumors. The considerable discrepancy in the molecular weight of MTX (454 Da) and albumin (about 67 000 Da) tempted researchers to load multiple drug molecules on one carrier molecule. It was supposed that the optimal… 

Antitumor activity of methotrexate‐albumin conjugates in rats bearing a Walker‐256 carcinoma

MTX‐albumin conjugates show therapeutic activity in vivo without toxic side effects and are evaluated for the combination treatment with MTX and MTX‐ albumin, with complete remission in all 20 rats.

Efficacy and tolerability of an aminopterin–albumin conjugate in tumor-bearing rats

In this comparative study, the AMPT–SA conjugate showed high antitumor activity in vivo and a favorable toxicity compared to low-molecular-weight AMPT, which seems to be an effective tool for selective tumor drug targeting.

In Vitro and in Vivo Antitumor Activity of Methotrexate Conjugated to Human Serum Albumin in Human Cancer Cells 1

MTX-HSA is effectively taken up by the cells via albumin receptoror folate receptor-mediated endocytosis and time-dependently released as an active compound into the cytosol to exert an inhibiting effect on TS and to induce cell cycle alterations.

In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.

MTX-HSA is effectively taken up by the cells via albumin receptor- or folate receptor-mediated endocytosis and time-dependently released as an active compound into the cytosol to exert an inhibiting effect on TS and to induce cell cycle alterations.

Pre‐clinical evaluation of a methotrexate–albumin conjugate (MTX‐HSA) in human tumor xenografts in vivo

The improved therapeutic effects seen in 3 xenograft models under MTX‐HSA treatment are promising and might be due to specific accumulation of the compound in solid tumors owing to their enhanced permeability and retention effect.

Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy.

  • Xinquan LiuR. Mohanty D. Ghosh
  • Biology, Chemistry
    Journal of controlled release : official journal of the Controlled Release Society
  • 2020

Drug conjugates with albumin and transferrin

This review covers the patent literature on the development of transferrin and albumin drug conjugates from 1985 onwards, with emphasis on the patent applications from the past 2 - 3 years.

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

  • F. Kratz
  • Biology, Chemistry
    Journal of controlled release : official journal of the Controlled Release Society
  • 2008

Albumin–Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells

The engineered BSA–MTX prodrug analogues which undergo intracellular reactivation and facilitate antiproliferative activities following their entrance into glioma cells are engineered.
...